{"id":"vildagliptin","rwe":[],"tags":[{"label":"vildagliptin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Dipeptidyl peptidase 4","category":"target"},{"label":"DPP4","category":"gene"},{"label":"DPP9","category":"gene"},{"label":"DPP8","category":"gene"},{"label":"A10BD08","category":"atc"},{"label":"Active","category":"status"},{"label":"Diabetes mellitus type 2","category":"indication"},{"label":"Dipeptidyl-Peptidase IV Inhibitors","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Hypoglycemic Agents","category":"pharmacology"},{"label":"Protease Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":2167.755,"date":"","count":472,"signal":"Pemphigoid","source":"DrugCentral FAERS","actionTaken":"Reported 472 times (LLR=2168)"},{"llr":255.046,"date":"","count":136,"signal":"Lactic acidosis","source":"DrugCentral FAERS","actionTaken":"Reported 136 times (LLR=255)"},{"llr":197.596,"date":"","count":279,"signal":"Acute kidney injury","source":"DrugCentral FAERS","actionTaken":"Reported 279 times (LLR=198)"},{"llr":191.311,"date":"","count":132,"signal":"Hypoglycaemia","source":"DrugCentral FAERS","actionTaken":"Reported 132 times (LLR=191)"},{"llr":165.611,"date":"","count":75,"signal":"Diabetes mellitus inadequate control","source":"DrugCentral FAERS","actionTaken":"Reported 75 times (LLR=166)"},{"llr":122.874,"date":"","count":89,"signal":"Hyperglycaemia","source":"DrugCentral FAERS","actionTaken":"Reported 89 times (LLR=123)"},{"llr":105.221,"date":"","count":96,"signal":"Hyperkalaemia","source":"DrugCentral FAERS","actionTaken":"Reported 96 times (LLR=105)"},{"llr":104.228,"date":"","count":36,"signal":"Euglycaemic diabetic ketoacidosis","source":"DrugCentral FAERS","actionTaken":"Reported 36 times (LLR=104)"},{"llr":103.145,"date":"","count":51,"signal":"Glycosylated haemoglobin increased","source":"DrugCentral FAERS","actionTaken":"Reported 51 times (LLR=103)"},{"llr":91.65,"date":"","count":175,"signal":"Drug interaction","source":"DrugCentral FAERS","actionTaken":"Reported 175 times (LLR=92)"},{"llr":89.15,"date":"","count":61,"signal":"Cerebral infarction","source":"DrugCentral FAERS","actionTaken":"Reported 61 times (LLR=89)"},{"llr":83.057,"date":"","count":52,"signal":"Diabetic ketoacidosis","source":"DrugCentral FAERS","actionTaken":"Reported 52 times (LLR=83)"},{"llr":74.63,"date":"","count":96,"signal":"Cardiac failure","source":"DrugCentral FAERS","actionTaken":"Reported 96 times (LLR=75)"},{"llr":74.627,"date":"","count":36,"signal":"Dermatitis bullous","source":"DrugCentral FAERS","actionTaken":"Reported 36 times (LLR=75)"},{"llr":70.192,"date":"","count":29,"signal":"Ketoacidosis","source":"DrugCentral FAERS","actionTaken":"Reported 29 times (LLR=70)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=VILDAGLIPTIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:07:10.934357+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:07:17.508522+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T01:07:11.007754+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=VILDAGLIPTIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:07:17.996871+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Dipeptidyl peptidase IV inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:07:19.041378+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL142703/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:07:18.700771+00:00"}},"allNames":"jalra","offLabel":[],"synonyms":["xiliarx","galvus","vildagliptin","jalra","NVP-LAF237","vildagliptin hydrochloride","vildagliptin HCl"],"timeline":[{"date":"2007-09-26","type":"positive","source":"DrugCentral","milestone":"EMA approval"}],"approvals":[{"date":"2007-09-26","orphan":false,"company":"","regulator":"EMA"}],"brandName":"Jalra","ecosystem":[{"indication":"Diabetes mellitus type 2","otherDrugs":[{"name":"acarbose","slug":"acarbose","company":"Bayer Hlthcare"},{"name":"acetohexamide","slug":"acetohexamide","company":"Lilly"},{"name":"albiglutide","slug":"albiglutide","company":"Glaxosmithkline Llc"},{"name":"alogliptin","slug":"alogliptin","company":"Takeda Pharms Usa"}],"globalPrevalence":537000000}],"mechanism":{"target":"Dipeptidyl peptidase 4","targets":[{"gene":"DPP4","source":"DrugCentral","target":"Dipeptidyl peptidase 4","protein":"Dipeptidyl peptidase 4"},{"gene":"DPP9","source":"DrugCentral","target":"Dipeptidyl peptidase 9","protein":"Dipeptidyl peptidase 9"},{"gene":"DPP8","source":"DrugCentral","target":"Dipeptidyl peptidase 8","protein":"Dipeptidyl peptidase 8"},{"gene":"FAP","source":"DrugCentral","target":"Prolyl endopeptidase FAP","protein":"Prolyl endopeptidase FAP"}],"modality":"Small Molecule","drugClass":"vildagliptin","explanation":"","oneSentence":"","technicalDetail":"Vildagliptin selectively and reversibly inhibits DPP-4, a key enzyme involved in the inactivation of incretin hormones, thereby increasing the levels of active incretin hormones, enhancing the release of insulin and decreasing the release of glucagon by the pancreas."},"commercial":{"revenueYear":2025,"annualRevenue":159,"revenueSource":"SEC 8-K Novartis (2024-10-29)","revenueCurrency":"USD","revenueConfidence":"verified (SEC filing)","revenueExtractedAt":"2026-04-01T11:47:51.733316","revenueExtractedBy":"revenue-sec"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3642","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=VILDAGLIPTIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=VILDAGLIPTIN","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T16:09:00.165708","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:07:20.461125+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"metformin","drugSlug":"metformin","fdaApproval":"1995-03-03","patentExpiry":"May 1, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"rosiglitazone","drugSlug":"rosiglitazone","fdaApproval":"1999-05-25","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"glimepiride","drugSlug":"glimepiride","fdaApproval":"1995-11-30","genericCount":17,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"pioglitazone","drugSlug":"pioglitazone","fdaApproval":"1999-07-15","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"sitagliptin","drugSlug":"sitagliptin","fdaApproval":"2006-10-16","patentExpiry":"Feb 25, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"alogliptin","drugSlug":"alogliptin","fdaApproval":"2013-01-25","patentExpiry":"Jun 27, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"saxagliptin","drugSlug":"saxagliptin","fdaApproval":"2009-07-31","patentExpiry":"Nov 30, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"linagliptin","drugSlug":"linagliptin","fdaApproval":"2011-05-02","patentExpiry":"Sep 5, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"vildagliptin","indications":{"approved":[{"name":"Diabetes mellitus type 2","source":"DrugCentral","snomedId":44054006,"regulator":"FDA","usPrevalence":37300000,"globalPrevalence":537000000,"prevalenceMethod":"curated","prevalenceSource":"IDF Diabetes Atlas, 2024"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"metformin","brandName":"metformin","genericName":"metformin","approvalYear":"1995","relationship":"same-class"},{"drugId":"rosiglitazone","brandName":"rosiglitazone","genericName":"rosiglitazone","approvalYear":"1999","relationship":"same-class"},{"drugId":"glimepiride","brandName":"glimepiride","genericName":"glimepiride","approvalYear":"1995","relationship":"same-class"},{"drugId":"pioglitazone","brandName":"pioglitazone","genericName":"pioglitazone","approvalYear":"1999","relationship":"same-class"},{"drugId":"sitagliptin","brandName":"sitagliptin","genericName":"sitagliptin","approvalYear":"2006","relationship":"same-class"},{"drugId":"alogliptin","brandName":"alogliptin","genericName":"alogliptin","approvalYear":"2013","relationship":"same-class"},{"drugId":"saxagliptin","brandName":"saxagliptin","genericName":"saxagliptin","approvalYear":"2009","relationship":"same-class"},{"drugId":"linagliptin","brandName":"linagliptin","genericName":"linagliptin","approvalYear":"2011","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02176681","phase":"PHASE4","title":"A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2014-06","conditions":["Haemodialyzed, Type 2 Diabetes"],"enrollment":70,"completionDate":"2017-10"},{"nctId":"NCT06851962","phase":"PHASE4","title":"Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2025-05-26","conditions":["Diabetes Mellitus Type 2"],"enrollment":504,"completionDate":"2026-06-30"},{"nctId":"NCT06142656","phase":"PHASE2,PHASE3","title":"Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome","status":"RECRUITING","sponsor":"October 6 University","startDate":"2023-11-25","conditions":["Poly Cystic Ovary Syndrome"],"enrollment":60,"completionDate":"2026-02-01"},{"nctId":"NCT04300790","phase":"PHASE2","title":"Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients","status":"COMPLETED","sponsor":"MedSIR","startDate":"2020-10-23","conditions":["Breast Cancer"],"enrollment":69,"completionDate":"2025-03-16"},{"nctId":"NCT07077525","phase":"PHASE4","title":"Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2023-06-01","conditions":["Type 2 Diabetes"],"enrollment":196,"completionDate":"2024-08-31"},{"nctId":"NCT04410341","phase":"PHASE1,PHASE2","title":"The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2020-05-01","conditions":["Major Depressive Disorder"],"enrollment":0,"completionDate":"2024-12-01"},{"nctId":"NCT04761861","phase":"PHASE2","title":"Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2021-02-16","conditions":["Schizophrenia","Dyslipidemias"],"enrollment":0,"completionDate":"2025-12-31"},{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":["Diabetes Mellitus, Type 2","Cardiovascular Diseases"],"enrollment":714582,"completionDate":"2018-06-25"},{"nctId":"NCT04841096","phase":"PHASE3","title":"Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2023-03-21","conditions":["Type 2 Diabetes"],"enrollment":162,"completionDate":"2024-05-15"},{"nctId":"NCT01242228","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-10-21","conditions":["Type 2 Diabetes Mellitus"],"enrollment":106,"completionDate":"2012-06-06"},{"nctId":"NCT06951334","phase":"NA","title":"Clinical Trial of Vildagliptin in Early Parkinson's Disease","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2025-06-01","conditions":["Parkinson's Disease"],"enrollment":66,"completionDate":"2026-12-31"},{"nctId":"NCT06913101","phase":"NA","title":"Comparison of Once-Weekly Trelagliptin vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"PNS Hafeez - Naval Hospital","startDate":"2024-11-15","conditions":["Type 2 Diabetes Mellitus (T2DM)"],"enrollment":102,"completionDate":"2025-05-15"},{"nctId":"NCT06889909","phase":"NA","title":"Comparison of Once-Weekly Trelagliptin Vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lahore General Hospital","startDate":"2024-12-15","conditions":["Type 2 Diabetes Mellitus (T2DM)"],"enrollment":102,"completionDate":"2025-06-15"},{"nctId":"NCT06068686","phase":"NA","title":"Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2022-10-01","conditions":["Type 2 Diabetes"],"enrollment":70,"completionDate":"2024-12-01"},{"nctId":"NCT06313008","phase":"NA","title":"Empagliflozin Versus Vildagliptin in CAD Patients With T2DM","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2023-08-10","conditions":["Coronary Artery Disease","Type 2 Diabetes"],"enrollment":120,"completionDate":"2024-10-10"},{"nctId":"NCT03939624","phase":"","title":"Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-10-01","conditions":["Type2 Diabetes","Myocardial Infarction","Ischemic Stroke","Cardiovascular Death","Heart Failure","All-Cause Mortality"],"enrollment":419734,"completionDate":"2019-10-01"},{"nctId":"NCT04017221","phase":"","title":"Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-10-01","conditions":["Diabetes Mellitus, Type 2","Urosepsis","Diabetic Ketoacidosis","Lower Extremity Amputation"],"enrollment":1249636,"completionDate":"2019-12-01"},{"nctId":"NCT06570980","phase":"","title":"Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.","status":"RECRUITING","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-08-25","conditions":["Type 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin"],"enrollment":200,"completionDate":"2024-08-30"},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":["Type2diabetes"],"enrollment":938,"completionDate":"2025-06"},{"nctId":"NCT03918148","phase":"","title":"Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2018-01-15","conditions":["Type 2 Diabetes Mellitus"],"enrollment":1150,"completionDate":"2023-12-31"},{"nctId":"NCT06248801","phase":"PHASE1","title":"Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets","status":"UNKNOWN","sponsor":"Bio-innova Co., Ltd","startDate":"2024-09-05","conditions":["Healthy Subjects"],"enrollment":48,"completionDate":"2024-10-15"},{"nctId":"NCT06244407","phase":"PHASE1","title":"The Bioequivalence Study of Fixed-dose Combination of Vildagliptin and Metformin HCI 50/1000 mg FCT Under Fed Conditions","status":"UNKNOWN","sponsor":"International Bio service","startDate":"2024-05-23","conditions":["Healthy Volunteer"],"enrollment":40,"completionDate":"2024-06-02"},{"nctId":"NCT03014479","phase":"PHASE4","title":"Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-02-18","conditions":["Type 2 Diabetes"],"enrollment":219,"completionDate":"2017-10-21"},{"nctId":"NCT05369793","phase":"PHASE3","title":"Clinical Study Evaluating the Safety and Efficacy of Roflumilast in Type 2 Diabetic Patients With Diabetic Neuropathy","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-08-01","conditions":["Type 2 Diabetes (Adult Onset)","Diabetic Neuropathies"],"enrollment":60,"completionDate":"2023-10-10"},{"nctId":"NCT05366868","phase":"PHASE4","title":"Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"National Center for Global Health and Medicine, Japan","startDate":"2022-05-26","conditions":["Diabetes Mellitus, Type 2"],"enrollment":567,"completionDate":"2027-03-31"},{"nctId":"NCT06103747","phase":"PHASE1","title":"Bioequivalence Study to Compare Metformin / Vildagliptin (850 mg/50 mg) Versus Galvumet®","status":"COMPLETED","sponsor":"Reseach Laboratory of Clinical and Experimental Pharmacology","startDate":"2023-02-21","conditions":["Fed Conditions"],"enrollment":18,"completionDate":"2023-08-15"},{"nctId":"NCT06073600","phase":"PHASE1","title":"Bioequivalence Study to Compare Metformin / Vildagliptin Versus Galvumet®","status":"COMPLETED","sponsor":"Reseach Laboratory of Clinical and Experimental Pharmacology","startDate":"2022-05-20","conditions":["Fed Conditions"],"enrollment":18,"completionDate":"2022-11-13"},{"nctId":"NCT06010992","phase":"PHASE2","title":"Nitazoxanide as Adjuvant Therapy in Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2023-10-01","conditions":["Diabetes Mellitus, Type 2"],"enrollment":70,"completionDate":"2025-01-01"},{"nctId":"NCT05902468","phase":"PHASE2,PHASE3","title":"Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2023-06-28","conditions":["Diabetes Mellitus, Type 2"],"enrollment":88,"completionDate":"2024-11-28"},{"nctId":"NCT03693560","phase":"PHASE4","title":"Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2018-10-08","conditions":["Coronary Artery Disease","Diabetes Mellitus, Type 2"],"enrollment":80,"completionDate":"2019-10-10"},{"nctId":"NCT02244164","phase":"NA","title":"Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.","status":"TERMINATED","sponsor":"Erasme University Hospital","startDate":"2014-10","conditions":["Type 2 Diabetes","Incretinomimetics","Pancreas"],"enrollment":5,"completionDate":"2023-02-13"},{"nctId":"NCT02849899","phase":"PHASE3","title":"Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2018-10-26","conditions":["Disorder Related to Renal Transplantation","Diabetes"],"enrollment":186,"completionDate":"2024-12"},{"nctId":"NCT05347459","phase":"","title":"Cognitive Protective Effect of Newer Antidiabetic Drugs","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2022-03-02","conditions":["Type 2 Diabetes"],"enrollment":100,"completionDate":"2023-12"},{"nctId":"NCT05429554","phase":"","title":"The Effect of Metformin and DPP4 Inhibitors on Cognition and Cardiovascular Protection in Type 2 Diabetic Patients","status":"UNKNOWN","sponsor":"MTI University","startDate":"2022-06","conditions":["Type 2 Diabetes Mellitus"],"enrollment":60,"completionDate":"2022-09"},{"nctId":"NCT05359432","phase":"PHASE4","title":"Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Getz Pharma","startDate":"2020-07-01","conditions":["Type 2 Diabetes"],"enrollment":120,"completionDate":"2021-08-18"},{"nctId":"NCT05337969","phase":"NA","title":"The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safety Profile of Test Product Compared to Reference Product Will be Assessed.","status":"COMPLETED","sponsor":"AET Laboratories Private Limited","startDate":"2015-12","conditions":["To Determine Bioequivalence Under Fed Conditions"],"enrollment":60,"completionDate":"2016-03"},{"nctId":"NCT05329844","phase":"NA","title":"The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safeyt Profile of Test Product Compared to Reference Product Will be Assessed.","status":"COMPLETED","sponsor":"AET Laboratories Private Limited","startDate":"2014-02","conditions":["Diabetes Mellitus"],"enrollment":66,"completionDate":"2015-04"},{"nctId":"NCT05329857","phase":"NA","title":"The Study Intends to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safety Profile of Test Product Compared to Reference Product Will be Evaluated.","status":"COMPLETED","sponsor":"AET Laboratories Private Limited","startDate":"2015-12","conditions":["To Determine Bioequivalence Under Fed Conditions"],"enrollment":60,"completionDate":"2016-03"},{"nctId":"NCT03958591","phase":"PHASE4","title":"Effects of Short-term Intensive De-escalation Therapy on Long-term Regimen Simplification","status":"UNKNOWN","sponsor":"Yanbing Li","startDate":"2019-05-01","conditions":["Diabetes type2"],"enrollment":274,"completionDate":"2022-12-31"},{"nctId":"NCT05102149","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"PegBio Co., Ltd.","startDate":"2021-09-30","conditions":["Type 2 Diabetes Mellitus (T2DM)"],"enrollment":672,"completionDate":"2025-04"},{"nctId":"NCT05041673","phase":"NA","title":"Anti-diabetic Drugs and Fatty Liver Management","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2021-02-23","conditions":["Fatty Liver, Nonalcoholic","Diabetes Mellitus, Type 2"],"enrollment":120,"completionDate":"2022-09-30"},{"nctId":"NCT02862470","phase":"","title":"Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2016-08-05","conditions":["Thyroid Cancer"],"enrollment":22,"completionDate":"2020-08-24"},{"nctId":"NCT04916093","phase":"PHASE4","title":"Safety and Efficacy of Antidiabetic Drugs in Recently Diagnosed Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2019-12-20","conditions":["Diabetes Mellitus, Type 2"],"enrollment":60,"completionDate":"2020-12-15"},{"nctId":"NCT00860288","phase":"PHASE2,PHASE3","title":"Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-02","conditions":["Diabetes Mellitus, Type 2"],"enrollment":1988,"completionDate":"2011-03"},{"nctId":"NCT00728351","phase":"PHASE3","title":"Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-06","conditions":["Diabetes Mellitus, Type 2"],"enrollment":317,"completionDate":""},{"nctId":"NCT04654676","phase":"PHASE4","title":"DPP4 Inhibitor on Glycemic Variability","status":"COMPLETED","sponsor":"University Malaysia Sarawak","startDate":"2018-09-15","conditions":["Diabetes Mellitus, Type 2"],"enrollment":12,"completionDate":"2019-08-31"},{"nctId":"NCT00468039","phase":"PHASE3","title":"A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-03-06","conditions":["Diabetes Mellitus, Type 2"],"enrollment":94,"completionDate":"2008-06-06"},{"nctId":"NCT01309698","phase":"PHASE4","title":"Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-02","conditions":["Type 2 Diabetes"],"enrollment":24,"completionDate":""},{"nctId":"NCT00382096","phase":"PHASE3","title":"Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-09","conditions":["Diabetes Mellitus, Type 2"],"enrollment":1179,"completionDate":"2008-06-03"},{"nctId":"NCT00646542","phase":"PHASE3","title":"Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-03","conditions":["Diabetes Mellitus, Type 2"],"enrollment":525,"completionDate":""},{"nctId":"NCT00765830","phase":"PHASE3","title":"Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-09","conditions":["Diabetes Mellitus, Type 2","Renal Insufficiency"],"enrollment":349,"completionDate":"2011-04"},{"nctId":"NCT00383578","phase":"PHASE3","title":"Efficacy and Safety of Vildagliptin Compared to Metformin in Elderly Drug Naive Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-09","conditions":["Diabetes Mellitus, Type 2"],"enrollment":335,"completionDate":""},{"nctId":"NCT00818571","phase":"PHASE1,PHASE2","title":"Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-12","conditions":["Renal Impairment","Diabetes"],"enrollment":96,"completionDate":""},{"nctId":"NCT01159249","phase":"PHASE3","title":"Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-06","conditions":["Type 2 Diabetes"],"enrollment":245,"completionDate":"2012-01"},{"nctId":"NCT00106340","phase":"PHASE3","title":"Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-03","conditions":["Diabetes Mellitus, Type 2"],"enrollment":3118,"completionDate":"2008-05-20"},{"nctId":"NCT00099853","phase":"PHASE3","title":"Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-05","conditions":["Diabetes Mellitus, Type 2"],"enrollment":362,"completionDate":"2008-01"},{"nctId":"NCT00616811","phase":"PHASE3","title":"Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-01","conditions":["Diabetes Mellitus, Type 2"],"enrollment":148,"completionDate":"2010-10"},{"nctId":"NCT00102466","phase":"PHASE3","title":"Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-01","conditions":["Diabetes Mellitus, Type 2"],"enrollment":1007,"completionDate":"2009-01"},{"nctId":"NCT00633997","phase":"PHASE1,PHASE2","title":"Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"Novartis","startDate":"2008-02","conditions":["Diabetes Mellitus, Type 2"],"enrollment":22,"completionDate":""},{"nctId":"NCT00894868","phase":"PHASE4","title":"Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-05","conditions":["Congestive Heart Failure","Type II Diabetes Mellitus"],"enrollment":798,"completionDate":"2012-08"},{"nctId":"NCT00821977","phase":"PHASE2,PHASE3","title":"Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-11","conditions":["Diabetes Mellitus, Type 2"],"enrollment":338,"completionDate":"2010-10"},{"nctId":"NCT00260156","phase":"PHASE3","title":"A Clinical Study to Assess the Effect of Vildagliptin on Beta Cell Function in Drug Naive Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-11","conditions":["Diabetes Mellitus, Type 2"],"enrollment":59,"completionDate":"2008-12"},{"nctId":"NCT00770081","phase":"PHASE3","title":"Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-09","conditions":["Diabetes Mellitus, Type 2","Renal Insufficiency"],"enrollment":75,"completionDate":"2011-04"},{"nctId":"NCT00396357","phase":"PHASE3","title":"Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin Alone","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-10","conditions":["Diabetes Mellitus, Type 2"],"enrollment":914,"completionDate":""},{"nctId":"NCT02803892","phase":"PHASE2","title":"Monotherapy With Rapamycin in Long-standing Type 1 Diabetes","status":"COMPLETED","sponsor":"Piemonti Lorenzo","startDate":"2016-05","conditions":["Diabetes Mellitus, Type 1"],"enrollment":55,"completionDate":"2019-03"},{"nctId":"NCT01528254","phase":"PHASE4","title":"VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03-30","conditions":["Type 2 Diabetes Mellitus"],"enrollment":2004,"completionDate":"2019-04-04"},{"nctId":"NCT00936234","phase":"PHASE2,PHASE3","title":"Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).","status":"WITHDRAWN","sponsor":"Johann Wolfgang Goethe University Hospital","startDate":"2009-07","conditions":["SDF-1 is an Important Cytokine for Neovascularization. Cleavage of SDF-1 is Reduced by DPPIV Inhibitors"],"enrollment":0,"completionDate":"2013-05"},{"nctId":"NCT04485845","phase":"PHASE4","title":"Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications Progression","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2019-11-01","conditions":["Metabolic Syndrome","Diabete Type 2","Kidney Insufficiency"],"enrollment":39,"completionDate":"2020-09-30"},{"nctId":"NCT04237493","phase":"PHASE4","title":"Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan","status":"COMPLETED","sponsor":"University of Jordan","startDate":"2017-02-14","conditions":["Diabetes Mellitus, Type 2"],"enrollment":687,"completionDate":"2017-07-24"},{"nctId":"NCT00390520","phase":"PHASE3","title":"Efficacy and Safety of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-09","conditions":["Diabetes Mellitus, Type 2"],"enrollment":28,"completionDate":"2007-09"},{"nctId":"NCT03804411","phase":"PHASE4","title":"Prognostic Predictors of Response to Hypoglycemic Therapy","status":"UNKNOWN","sponsor":"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health","startDate":"2017-08-01","conditions":["Diabetes Mellitus, Type 2"],"enrollment":800,"completionDate":"2020-05"},{"nctId":"NCT03577184","phase":"","title":"Evaluating the Glycemic Control wIth Vildagliptin and Metformin Combination Therapy.","status":"WITHDRAWN","sponsor":"Clinision","startDate":"2018-07","conditions":["Diabetes Mellitus, Type 2"],"enrollment":0,"completionDate":"2019-03"},{"nctId":"NCT04087525","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics and Safety of HIP1701 in Healthy Subjects","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2018-10-23","conditions":["Health, Subjective"],"enrollment":31,"completionDate":"2018-11-27"},{"nctId":"NCT04081857","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics and Safety of HCP1704 in Healthy Subjects","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2019-06-03","conditions":["Health, Subjective"],"enrollment":48,"completionDate":"2019-08-05"},{"nctId":"NCT03983551","phase":"PHASE4","title":"Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas","status":"COMPLETED","sponsor":"Changhua Christian Hospital","startDate":"2016-03-01","conditions":["Type 2 Diabetes Mellitus","Proteinuria"],"enrollment":101,"completionDate":"2018-02-28"},{"nctId":"NCT01862263","phase":"PHASE4","title":"Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-05","conditions":["Type 2 Diabetes Mellitus"],"enrollment":191,"completionDate":"2015-07"},{"nctId":"NCT02475070","phase":"PHASE4","title":"Vildagliptin Versus Dapagliflozin on Glucagon","status":"COMPLETED","sponsor":"Lund University","startDate":"2016-01","conditions":["Type 2 Diabetes"],"enrollment":28,"completionDate":"2017-06"},{"nctId":"NCT03925701","phase":"PHASE3","title":"Clinical Study Evaluating Vildagliptin Versus Vildagliptin/Metformin on NAFLD With DM","status":"RECRUITING","sponsor":"Sherief Abd-Elsalam","startDate":"2019-04-01","conditions":["dm"],"enrollment":120,"completionDate":"2028-12"},{"nctId":"NCT02853630","phase":"PHASE4","title":"A Clinical Trial to Study the Effects of Two Drugs, Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals","startDate":"2013-12","conditions":["TYpe 2 Diabetes Mellitus"],"enrollment":203,"completionDate":"2018-12"},{"nctId":"NCT01882907","phase":"PHASE4","title":"Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes","status":"COMPLETED","sponsor":"Pusan National University Hospital","startDate":"2009-12","conditions":["Type 2 Diabetes"],"enrollment":287,"completionDate":"2013-03"},{"nctId":"NCT03819127","phase":"PHASE4","title":"Vildagliptin in Older Adults With Diabetes and Mild Cognitive Impairment","status":"COMPLETED","sponsor":"University of Catania","startDate":"2015-01","conditions":["Mild Cognitive Impairment"],"enrollment":60,"completionDate":"2016-09"},{"nctId":"NCT01404676","phase":"PHASE4","title":"The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2010-06","conditions":["Type 2 Diabetes Mellitus"],"enrollment":34,"completionDate":"2012-05"},{"nctId":"NCT03178591","phase":"PHASE4","title":"Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor","status":"COMPLETED","sponsor":"Chiang Mai University","startDate":"2014-10","conditions":["Diabetes Mellitus, Type 2","Ischemic Heart Disease"],"enrollment":43,"completionDate":"2018-07"},{"nctId":"NCT03563794","phase":"PHASE4","title":"Efficacy and Safety of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion in Uncontrolled Type 2 Diabetes","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2018-06-10","conditions":["T2DM"],"enrollment":400,"completionDate":"2019-12-10"},{"nctId":"NCT03500900","phase":"NA","title":"Vildagliptin on Gastric Accommodation","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2016-03-01","conditions":["Healthy"],"enrollment":20,"completionDate":"2017-01-01"},{"nctId":"NCT02312427","phase":"PHASE4","title":"DPP-4 Inhibitor and Serum BNP Level of Diabetic Patients With Congestive Heart Failure","status":"COMPLETED","sponsor":"Mitsui Memorial Hospital","startDate":"2015-01","conditions":["Heart Failure","Diabetes Mellitus"],"enrollment":10,"completionDate":"2016-03"},{"nctId":"NCT02832999","phase":"PHASE4","title":"Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes","status":"COMPLETED","sponsor":"Yaounde Central Hospital","startDate":"2016-01","conditions":["Type 2 Diabetes Mellitus"],"enrollment":14,"completionDate":"2016-12"},{"nctId":"NCT02089438","phase":"PHASE4","title":"DPP-4 Inhibition, Incretins and Islet Function","status":"COMPLETED","sponsor":"Lund University","startDate":"2014-05","conditions":["Type 2 Diabetes"],"enrollment":24,"completionDate":"2017-08"},{"nctId":"NCT03253562","phase":"PHASE4","title":"Metformin Versus Vildagliptin for Diabetic Hypertensive Patients","status":"COMPLETED","sponsor":"MTI University","startDate":"2017-02-01","conditions":["Reducing the Elevated Blood Pressure for Diabetic Hypertensive Patients"],"enrollment":120,"completionDate":"2017-08-01"},{"nctId":"NCT00300287","phase":"PHASE3","title":"A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild Hyperglycemia","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-02-20","conditions":["Diabetes Mellitus, Type 2"],"enrollment":150,"completionDate":"2007-06-26"},{"nctId":"NCT00099892","phase":"PHASE3","title":"Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-05","conditions":["Diabetes Mellitus, Type 2"],"enrollment":544,"completionDate":"2005-09"},{"nctId":"NCT01822548","phase":"PHASE3","title":"Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria di Parma","startDate":"2010-10","conditions":["Type 2 Diabetes"],"enrollment":64,"completionDate":"2015-01"},{"nctId":"NCT01196546","phase":"PHASE4","title":"Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-03","conditions":["Type 2 Diabetes Mellitus"],"enrollment":161,"completionDate":"2011-10"},{"nctId":"NCT02007278","phase":"PHASE4","title":"Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-01-03","conditions":["Type 2 Diabetes","Hypoglycemia"],"enrollment":40,"completionDate":"2016-02-22"},{"nctId":"NCT01827280","phase":"PHASE4","title":"Acute and Short-term Chronic Effects of Galvus (Vildagliptin) in Diabetes Type 2 Obese Women","status":"COMPLETED","sponsor":"Rio de Janeiro State University","startDate":"2013-04","conditions":["1- Microvascular Function","2-oxidative Stress","3-inflammation"],"enrollment":40,"completionDate":"2016-11"},{"nctId":"NCT01582308","phase":"PHASE1","title":"A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-06-21","conditions":["Type 2 Diabetes Mellitus"],"enrollment":22,"completionDate":"2012-12-14"},{"nctId":"NCT00120536","phase":"PHASE3","title":"Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-06","conditions":["Diabetes Mellitus, Type 2"],"enrollment":288,"completionDate":"2006-07"},{"nctId":"NCT00101803","phase":"PHASE3","title":"Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-01","conditions":["Diabetes Mellitus, Type 2"],"enrollment":527,"completionDate":"2006-01"},{"nctId":"NCT00099918","phase":"PHASE3","title":"Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-05","conditions":["Diabetes Mellitus, Type 2"],"enrollment":717,"completionDate":"2005-09"},{"nctId":"NCT01766778","phase":"PHASE4","title":"Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-05-13","conditions":["Type-2 Diabetes Mellitus"],"enrollment":117,"completionDate":"2015-10-22"}],"_emaApprovals":[{"date":"2007-09-26","status":"Authorised","company":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"012358","UNII":"I6B4B2U96P","CHEBI":"CHEBI:135285","INN_ID":"8399","RXNORM":"596554","UMLSCUI":"C1570906","chemblId":"CHEMBL142703","ChEMBL_ID":"CHEMBL142703","KEGG_DRUG":"D07080","DRUGBANK_ID":"DB04876","PDB_CHEM_ID":"LF7","PUBCHEM_CID":"6918537","SNOMEDCT_US":"428611002","IUPHAR_LIGAND_ID":"6310","SECONDARY_CAS_RN":"924914-75-0","MESH_DESCRIPTOR_UI":"D000077597"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.67 hours","clearance":"9.9 mL/min/kg","bioavailability":"85%","fractionUnbound":"0.8851236182%","volumeOfDistribution":"1.03 L/kg"},"publicationCount":1375,"therapeuticAreas":["Metabolic"],"_revenueScrapedAt":"2026-04-01 10:47:51.756471+00","atcClassification":{"source":"DrugCentral","atcCode":"A10BD08","allCodes":["A10BD08","A10BH02"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"2007","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:07:20.461125+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}